Tags: Drug.
LCZ696 is an investigational combination drug consisting of two antihypertensives (blood pressure lowering drugs) valsartan and AHU-377 in a 1:1 mixture. It is being developed by Novartis. The combination is often described as a dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) although the two effects are achieved by two different molecules.In Phase II clinical trials LCZ696 was superior to valsartan alone in treating hypertension and well tolerated.
